Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

VJVirtual | IV vs subcut dara: relevance in COVID-19 pandemic

Rakesh Popat • 15 May 2020
Multiple Myeloma Daratumumab

Rakesh Popat, MBBS, MRCP, FRCPath, PhD, of University College London Hospitals NHS Foundation Trust, London, UK, discusses the use of subcutaneous vs intravenous daratumumab, and the importance of a subcutaenous format in light of the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Rakesh Popat

Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN
3:11
Oral toxicities associated with talquetamab in RRMM: insights from REALiTAL and TALISMAN
Rakesh Popat • 5 Dec 2025
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM
1:38
Patient questionnaire (VRAT) to assess ocular toxicities related to belantamab mafodotin in RRMM
Rakesh Popat • 5 Dec 2025
Sequencing bispecific antibodies and CAR-T in multiple myeloma
1:58
Sequencing bispecific antibodies and CAR-T in multiple myeloma
Rakesh Popat • 5 Dec 2025
Treatment goals and preferences in RRMM: patients and physicians
2:29
Treatment goals and preferences in RRMM: patients and physicians
Rakesh Popat • 20 Sep 2025

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Rakesh Popat • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Rakesh Popat • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Rakesh Popat • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Rakesh Popat • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals